Ahead of AACR 2025, Charles River announces updates to its comprehensive portfolio to support the discovery and development of novel oncology drugs.

This study is led by Prof. Kenneth To (School of Pharmacy, The Chinese University of Hong Kong) and Dr. William Cho ...

Genialis, the RNA biomarker company, today announced two new studies demonstrating how predictive algorithms can drive better outcomes for patients, providers, and drug developers. In poster ...

Somewhere in the body of a patient, a small clump of cells, growing undetected, has begun to form a tumor. It has yet to cause pain or visible symptoms of illness. Several months from now, or perhaps ...

Explore the differences between turmeric and curcumin, their unique health benefits, and how to determine which supplement ...

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ's dense tissue to define the ...

OBI Pharma Announces Poster Presentations at the AACR 2025 Annual Meeting for OBI-992 and OBI-902 Antibody-Drug Conjugates (ADCs), GlycOBI® and ThiOBI® ADC enabling technologies, the OBI-3424 prodrug, ...

Human α–lactalbumin made lethal to tumor cells (HAMLET) is the first member in a new family of protein–lipid complexes that kills tumor cells with high selectivity. The protein component of ...